DIGITAL TOOLS CAN BE USED TO CREATE ADDITIONAL MODALITIES OF INFORMATION, which help to cut through the heterogeneity present in these disorders. These dimensions might include accelerometry to understand aspects of dyskinesia, or looking at ways of processing auditory information and visual features, such as word choice and facial expressions in response to prompts. All of this information paints a picture in a digital landscape, which can help to redefine current heterogeneous patient populations into more homogeneous sets of subpopulations across the neurological spectrum. Digital tools can help us tease apart heterogeneity and zero in on patients most likely to respond to a medication.
JOHN REYNDERS is chief data sciences officer at Neumora Therapeutics.